Dr. Klaus Lindpaintner Joins SDI as Vice President of R&D / Chief Scientific Officer

NEWARK, Del.--(BUSINESS WIRE)--

SDI (Strategic Diagnostics Inc., Nasdaq: SDIX), a provider of biotechnology-based products and services, today announced that Dr. Klaus Lindpaintner will be joining the Company as Vice President of Research & Development and Chief Scientific Officer (CSO), effective February 1, 2010.

Prior to joining SDI, Dr. Lindpaintner was with F. Hoffmann-La Roche Ltd. and most recently served as Director of the “Roche Molecular Medicine Laboratories” at the company’s headquarters in Basel, Switzerland, and as Roche’s Global Head, Molecular Medicines Policy and External Affairs, coordinating the company’s efforts and activities in implementing biomarker research based on genetics, genomics, proteomics, and associated disciplines from early discovery to late-stage clinical trials. He has co-authored more than 200 scientific papers, and has held honorary and adjunct professorships at the University of London Guy’s and St. Thomas, Jiao Tong University in Shanghai, Stanford University and the University of Vienna. He has served on numerous working groups and advisory panels for trade organizations, regulatory authorities and non-governmental institutions on issues related to scientific aspects as well as ethical and societal impacts of novel technologies in biomedicine. Dr. Lindpaintner is a member of a number of Editorial Boards, including The Pharmacogenomics Journal, J Comm Biotechnology, and Pharmacogenomics. He is a co-inventor on several patents.

Dr. Lindpaintner graduated from the Innsbruck University Medical School with a degree in Medicine and from Harvard University with a degree in Public Health. He pursued postgraduate training and specialization in Internal Medicine, Cardiology, and Genetics in the United States and Germany and holds board certifications in these specialties. Prior to joining industry, he practiced clinical cardiology and pursued academic research in the areas of cardiovascular disease, molecular genetics, and genetic epidemiology as an Associate Professor of Medicine at Harvard Medical School. He is a Fellow of the American College of Physicians, the American Heart Association, and the American College for Medical Genetics.

Commenting on the announcement, Mr. Fran DiNuzzo, president and CEO of SDI, said, “We are extremely pleased to be adding someone with the background of Dr. Lindpaintner to the SDI management team. His insight and extraordinary experience will be a tremendous asset to SDI as we enhance our current offerings and continue in our strategic direction as an emerging contributor to the biotechnology and life sciences markets.”

About SDI

SDIX is a biotechnology company, expert at creating advantage by providing quality, innovative and effective immuno-solutions to the Pharmaceutical, Biotechnology, Diagnostics and Food Safety markets.

For 20 years, SDI has created antibodies that advance its customers’ immuno-based work – reducing time, labor and costs while increasing accuracy and reliability of results.

SDI offers a fully-integrated suite of immuno-solution capabilities, including its Genomic Antibody Technology ^TM (GAT) for diagnostic-grade clinical assays and research projects – from antibody candidate to critical high-quality reagent formulation. GAT enables fast and robust design and development of antibodies and antibody panels with high specificity, sensitivity and reliability. For more information, visit www.sdix.com.

This news release may contain forward-looking statements reflecting SDI's current expectations. When used in this press release, words like “anticipate,” “could,” “enable,” “estimate,” “intend,” “expect,” “believe,” “potential,” “will,” “should,” “project,” “plan” and similar expressions as they relate to SDI are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDI at this time. Such risks and uncertainties include, without limitation, changes in demand for products, the application of our technologies to various uses, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party, including AOAC, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDI's public filings with the U.S. Securities and Exchange Commission.